Edward Conner

Sangamo Therapeutics Inc (NASDAQ: SGMO) announced Monday it would acquire TxCell for about €72 million to complement its ex vivo gene editing program. In conjunction with the news, management reported treatment initiation for its first patient in a Phase 1/2 study of SB-318 for...